Research Analysts Issue Forecasts for ZVRA FY2026 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Analysts at Cantor Fitzgerald dropped their FY2026 earnings estimates for Zevra Therapeutics in a report released on Thursday, November 6th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn $0.43 per share for the year, down from their prior forecast of $0.55. Cantor Fitzgerald currently has a “Overweight” rating and a $24.00 target price on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. The business had revenue of $26.06 million during the quarter, compared to analyst estimates of $26.64 million. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%.

Other analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Tuesday, October 14th. Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday. Wall Street Zen cut Zevra Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 20th. JMP Securities reduced their price target on Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating for the company in a report on Wednesday, August 13th. Finally, Zacks Research downgraded Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $22.80.

Zevra Therapeutics Stock Performance

ZVRA traded down $0.29 during trading on Friday, hitting $8.80. The stock had a trading volume of 417,278 shares, compared to its average volume of 1,044,134. The firm has a market capitalization of $493.88 million, a P/E ratio of -41.90 and a beta of 1.52. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85. Zevra Therapeutics has a twelve month low of $6.19 and a twelve month high of $13.16. The company’s 50-day moving average price is $9.56 and its 200 day moving average price is $9.53.

Insiders Place Their Bets

In other news, Director John B. Bode bought 5,000 shares of the stock in a transaction on Tuesday, August 19th. The shares were bought at an average price of $9.16 per share, with a total value of $45,800.00. Following the completion of the acquisition, the director owned 45,000 shares of the company’s stock, valued at approximately $412,200. This trade represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Neil F. Mcfarlane sold 19,500 shares of Zevra Therapeutics stock in a transaction on Friday, October 10th. The shares were sold at an average price of $10.82, for a total value of $210,990.00. Following the completion of the sale, the chief executive officer directly owned 222,016 shares of the company’s stock, valued at approximately $2,402,213.12. This represents a 8.07% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.40% of the stock is currently owned by insiders.

Institutional Trading of Zevra Therapeutics

Large investors have recently added to or reduced their stakes in the business. Woodline Partners LP increased its stake in Zevra Therapeutics by 11.5% in the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock worth $34,571,000 after purchasing an additional 476,032 shares in the last quarter. Readystate Asset Management LP lifted its position in shares of Zevra Therapeutics by 924.6% in the 1st quarter. Readystate Asset Management LP now owns 683,032 shares of the company’s stock valued at $5,116,000 after acquiring an additional 616,370 shares in the last quarter. Retirement Planning Co of New England Inc. boosted its stake in Zevra Therapeutics by 6.9% in the 1st quarter. Retirement Planning Co of New England Inc. now owns 550,180 shares of the company’s stock worth $4,121,000 after purchasing an additional 35,348 shares during the period. Velan Capital Investment Management LP raised its stake in Zevra Therapeutics by 121.7% during the 1st quarter. Velan Capital Investment Management LP now owns 665,000 shares of the company’s stock valued at $4,981,000 after purchasing an additional 365,000 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Zevra Therapeutics by 2.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company’s stock valued at $1,148,000 after purchasing an additional 3,827 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.